Xian Zeng

Company: Byterna Therapeutics

Job title: Chief Executive Officer & Co-Founder

Bio:

Dr. Xian Zeng, the CEO and Co-Founder of Byterna Therapeutics, leads this enterprising startup at the vanguard of groundbreaking circular mRNA-based immunotherapies. Holding a PhD in pharmaceutical science from the National University of Singapore, he previously served as Associate Professor at Fudan University School of Pharmacy, spearheading interdisciplinary research in AI-empowered mRNA drug discovery. Under his visionary leadership, Byterna is pioneering SEAA (Safe, Effective, Accessible, Affordable) CAR-T therapies for global patients, leveraging proprietary circular mRNA platforms and targeted delivery systems.

Seminars:

Scarless Circular mRNA In Vivo CAR-T Exhibits Potent Pharmacological Efficacy in Preclinical Models 10:00 am

CellectLNP is a versatile platform for modular engineering of antibody-conjugated LNPs to achieve efficient and selective in vivo CAR cmRNA delivery to T cells cmCAR, a prolonged and enhanced CAR expression platform enabled by scarless circular mRNA technology, exhibits superior efficiency for in vivo engineering of CAR-T cells Robust anti-cancer activity and profound B cell-depletion…Read more

CEO Leaders Think Tank – Accelerating the Next Wave of RNA-Based Therapeutics & Vaccines to Develop Safe & Efficacious Drugs to Commercial Reality 2:20 pm

The Asian biopharmaceutical sector is thriving in RNA innovation, manufacturing advancements and strategic alliances to enhance the knowledge, skills, and experience across the region to become the powerhouse of commercial success. Hear from pioneering executive leaders across mRNA and next generation RNAs who will discuss their ambitions, strategies and challenges for the future of this…Read more

day: Conference Day One